Their upregulations in progressive patients suggested the potential pivotal molecular characteristics in shaping tumor immune evasion (figure 2G, I), which also implied the existence of synchronously upregulation of immune checkpoint pertinent genes, indicating this subset of patients may be latent candidate to benefit from PD-L2 or TIM3 pathway inhibitions. The gene discussed is HAVCR2; the disease is neoplasm.